Clinical Trials Logo

Advanced Solid Tumors clinical trials

View clinical trials related to Advanced Solid Tumors.

Filter by:

NCT ID: NCT05430555 Terminated - Clinical trials for Advanced Solid Tumors

A Phase 1/ 2, First-in-Human, Open-Label, Accelerated-Titration, Two-Part Clinical Trial of TK-8001 in Patients With HLA-A*02:01 Genotype and Advanced-Stage/ Metastatic MAGE-A1+ Solid Tumors

IMAG1NE
Start date: July 29, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

The aim of this study is to determine the safety, tolerability and anti-tumoral activity of autologous T cells transduced with a T cell receptor specific for MAGE-A1 in eligible patients with advanced solid tumors.

NCT ID: NCT05407675 Active, not recruiting - Clinical trials for Advanced Solid Tumors

A Study to Evaluate the Safety and Tolerability of BMS-986408 Alone and in Combination With Nivolumab or Nivolumab and Ipilimumab in Participants With Advanced Solid Tumors

Start date: August 2, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

The primary purpose of this study is to characterize the safety profile of BMS-986408 as monotherapy and in combination with nivolumab or nivolumab and ipilimumab to establish the maximum tolerated dose (MTD). The Recommended Phase 2 Dose (RP2D) that optimizes the pharmacokinetic/pharmacodynamic (PK/PD) relationship of BMS-986408 will also be determined.

NCT ID: NCT05394350 Terminated - Clinical trials for Advanced Solid Tumors

A Study of MK-1088 as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors (MK-1088-002)

Start date: July 7, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

The study will evaluate the safety, tolerability, and pharmacokinetics (PK) of MK-1088 in monotherapy and in combination with pembrolizumab in participants with advanced solid tumors who have not responded to conventional therapy. The effect of MK-1088 on tumor size will also be examined.

NCT ID: NCT05393063 Not yet recruiting - Clinical trials for Advanced Solid Tumors

A Study to Evaluate the Efficacy and Safety of AK127 in Patients With Advanced Solid Tumors

Start date: June 2022
Phase: Phase 1
Study type: Interventional

This study is to characterize the safety, tolerability and anti-tumor activity of AK127 as a single agent in adult subjects with advanced solid tumor malignancies.

NCT ID: NCT05389462 Recruiting - Clinical trials for Advanced Solid Tumors

A Study of Mipasetamab Uzoptirine (ADCT-601) in Participants With Solid Tumors

Start date: July 13, 2022
Phase: Phase 1
Study type: Interventional

The primary objective of this study is to identify the recommended phase 2 dose (RP2D) and/or the maximum tolerated dose (MTD), and characterize the safety and tolerability of ADCT-601 monotherapy and in combination with gemcitabine.

NCT ID: NCT05387928 Not yet recruiting - Clinical trials for Advanced Solid Tumors

A Study of KL340399 in Patients With Advanced Solid Tumors

Start date: May 2022
Phase: Phase 1
Study type: Interventional

This is a single center, open-label, dose increasing study to evaluate the safety, tolerability, pharmacokinetic(PK) profile, and antitumor efficacy of KL340399 injection in patients with advanced solid tumors.

NCT ID: NCT05379985 Recruiting - Clinical trials for Advanced Solid Tumors

Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS

Start date: May 31, 2022
Phase: Phase 1
Study type: Interventional

Evaluate the safety and tolerability of RMC-6236 in adults with specific RAS mutant advanced solid tumors.

NCT ID: NCT05378737 Recruiting - Clinical trials for Advanced Solid Tumors

Evaluate the Safety, Tolerability and Pharmacokinetic Characteristics of BAT8006 for Injection

Start date: July 6, 2022
Phase: Phase 1
Study type: Interventional

Objectives: To evaluate the safety and tolerability of BAT8006 for injection in patients with advanced solid tumors, explore the maximum tolerated dose (MTD), and provide the recommended dose for subsequent clinical trials.

NCT ID: NCT05367635 Recruiting - Clinical trials for Advanced Solid Tumors

A Study of SKB315 in Patients With Advanced Solid Tumors

Start date: March 16, 2022
Phase: Phase 1
Study type: Interventional

This is a multicenter, open-label, multiple-dose dose finding and expansion study to evaluate the safety, tolerability, pharmacokinetic(PK) profile, and anti-tumor efficacy of SKB315 for injection in patients with advanced solid tumors.

NCT ID: NCT05349409 Enrolling by invitation - Clinical trials for Advanced Solid Tumors

A Trial of the Combination of SHR-A1811 and Fluzoparib in HER2-Expressing Cancers

Start date: June 9, 2022
Phase: Phase 2
Study type: Interventional

The study is being conducted to evaluate safety, tolerability and preliminary efficacy of SHR-A1811 for Injection in combination with Fluzoparib Capsule for HER2-expressing advanced solid tumors of patients. To explore the reasonable dosage of dosage regimen of combination therapy for HER2-expressing advanced malignant tumors of patients.